SENP2 Regulates Hepatocellular Carcinoma Cell Growth by Modulating the Stability of β-catenin |
Shen, Huo-Jian
(Department of General Surgery, Renji hospital of Shanghai Jiao Tong University School of Medicine)
Zhu, Hong-Yi (Department of General Surgery, Renji hospital of Shanghai Jiao Tong University School of Medicine) Yang, Chao (Department of General Surgery, Renji hospital of Shanghai Jiao Tong University School of Medicine) Ji, Fu (Department of General Surgery, Renji hospital of Shanghai Jiao Tong University School of Medicine) |
1 | Chiu SY, Asai N, Costantini F, et al (2008). SUMO-specific protease 2 is essential for modulating p53-Mdm2 in development of trophoblast stem cell niches and lineages. PLoS Biol, 6, e310. DOI ScienceOn |
2 | David R (2010). Sumoylation: Targeting SUMO. Nat Rev Mol Cell Biol, 11, 387. |
3 | Di Bacco A, Gill G (2006). SUMO-specific proteases and the cell cycle. An essential role for SENP5 in cell proliferation. Cell Cycle, 5, 2310-3. DOI |
4 | Geiss-Friedlander R, Melchior F (2007). Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol, 8, 947-56. DOI |
5 | Haindl M, Harasim T, Eick T, et al (2008). The nucleolar SUMOspecific protease SENP3 reverses SUMO modification of nucleophosmin and is required for rRNA processing. EMBO Rep, 9, 273-9. DOI |
6 | Hang J, Dasso M (2002). Association of the human SUMO-1 protease SENP2 with the nuclear pore. J Biol Chem, 277, 19961-6. DOI |
7 | Huang H, He X (2008). Wnt/beta-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol, 20, 119-25. DOI ScienceOn |
8 | Itahana Y, Yeh ET, Zhang Y (2006). Nucleocytoplasmic shuttling modulates activity and ubiquitination-dependent turnover of SUMO-specific protease 2. Mol Cell Biol, 26, 4675-89. DOI |
9 | Kang X, Qi Y, Zuo Y, et al (2010). SUMO-specific protease 2 is essential for suppression of polycomb group proteinmediated gene silencing during embryonic development. Mol Cell, 38, 191-201. DOI |
10 | Lam AP, Gottardi CJ (2011). Beta-catenin signaling: a novel mediator of fibrosis and potential therapeutic target. Curr Opin Rheumatol, 23, 562-7. DOI |
11 | Li SJ, Hochstrasser M (1999). A new protease required for cellcycle progression in yeast. Nature, 398, 246-51. DOI |
12 | MacDonald BT, Tamai K, He X (2009). Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell, 17, 9-26. DOI |
13 | Vertegaal AC (2010). SUMO chains: polymeric signals. Biochem Soc Trans, 38, 46-49. DOI |
14 | Wang Y, Dasso M (2009). SUMOylation and deSUMOylation at a glance. J Cell Sci, 122, 4249-52. DOI |
15 | White BD, Chien AJ, Dawson DW (2012). Dysregulation of Wnt/beta-catenin signaling in gastrointestinal cancers. Gastroenterology, 142, 219-32. DOI |
16 | Woo CH, Abe J (2010). SUMO--a post-translational modification with therapeutic potential? Curr Opin Pharmacol, 10, 146-55. DOI |
17 | Zhang XF, Tan X, Zeng G, et al (2010). Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor alpha/phosphoinositide 3-kinase signaling. Hepatology, 52, 954-65. |
18 | Yeh JJ, Hsu NY, Hsu WH, et al (2005). Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer. Lung, 183, 177-83. DOI ScienceOn |
19 | Bawa-Khalfe T, Yeh ET (2010). SUMO Losing Balance: SUMO Proteases Disrupt SUMO Homeostasis to Facilitate Cancer Development and Progression. Genes Cancer, 1, 748-52. DOI |
20 | Cavard, C, S Colnot, V Audard, et al (2008). Wnt/beta-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology. Future Oncol, 4, 647-60. DOI |
21 | Cheng J, Bawa T, Lee P, et al (2006). Role of desumoylation in the development of prostate cancer. Neoplasia, 8, 667-76. DOI |
22 | Cheng J, Kang X, Zhang S, et al (2007). SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell, 131, 584-95. DOI |